Teva Announces Leadership Change in its Global Operations Group
2019年10月2日 - 9:00PM
ビジネスワイヤ(英語)
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) announced
today the retirement of Dr. Carlo de Notaristefani, and the
appointment of Eric Drapé as Executive Vice President, Global
Operations. Dr. de Notaristefani will step down from his role
effective immediately. Mr. Drapé will be based out of Teva’s global
headquarters in Israel.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191002005310/en/
Eric Drapé, Executive Vice President,
Global Operations at Teva. Photo credit: Reuven Kapuchinski (Photo:
Business Wire)
"After more than seven years leading Teva Global Operations,
Carlo de Notaristefani, will retire from Teva," said Kare Schultz,
Teva's President and CEO. "During his tenure, Carlo and his team
significantly improved the strength and performance of our global
operations and supply chain while at the same time continuing to
optimize the network, reduce cost and improve the competitiveness
of our products. I would like to thank Carlo for his numerous
contributions and leadership, and wishing him the very best in his
retirement.
"Eric is the right leader to succeed Carlo at this time and take
Teva Global Operations to the next level of performance, acting as
a central driver of Teva's mission and strategy. The organization
is well prepared to ensure a smooth transition."
About Eric Drapé
Mr. Drapé, age 58, joined Teva in 2014 and served in various
senior management positions, including as Executive Vice President
and Chief Quality Officer of the Teva Group (2015-present), head of
Teva's Biologics Operations (2014-2017), and Senior Vice President,
Technical Operations Steriles, Respiratory and Biologics
(2014-2015). Prior to joining Teva, Mr. Drapé served as Executive
Vice President, Technical Operations of Ipsen Pharma and served in
several leading positions at Novo Nordisk. Mr. Drapé holds a
Doctorate degree in Pharmacy and a DESS in Analytical Control of
Drugs from the Université Paris XI. He also received his Executive
MBA from the Scandinavian International Management Institute in
Copenhagen.
About Teva
Established in Israel in 1901, Teva Pharmaceutical Industries
Ltd. (NYSE and TASE: TEVA) has been developing and producing
medicines to improve people’s lives for more than a century. We are
a global leader in generic and specialty medicines with a portfolio
consisting of over 3,500 products in nearly every therapeutic area.
Around 200 million people around the world take a Teva medicine
every day, and are served by one of the largest and most complex
supply chains in the pharmaceutical industry. Along with our
established presence in generics, we have significant innovative
research and operations supporting our growing portfolio of
specialty and biopharmaceutical products. Learn more at
www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to our ability to successfully
execute a smooth lead of Global Operations transition as well as
our ability to retain and recruit qualified executives; our ability
to successfully compete in the marketplace; our substantial
indebtedness, which may limit our ability to incur additional
indebtedness, engage in additional transactions or make new
investments; compliance, regulatory and litigation matters; other
financial and economic risks; and other factors discussed in our
Quarterly Reports on Form 10-Q for the first and second quarter of
2019 and in our Annual Report on Form 10-K for the year ended
December 31, 2018, including in the sections captioned "Risk
Factors” and “Forward Looking Statements.” Forward-looking
statements speak only as of the date on which they are made, and we
assume no obligation to update or revise any forward-looking
statements or other information contained herein, whether as a
result of new information, future events or otherwise. You are
cautioned not to put undue reliance on these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191002005310/en/
IR Contacts United
States Kevin C. Mannix (215)
591-8912 Ran Meir 972 (3) 926-7516
PR Contacts United
States Kelley Dougherty (973) 658-0237
Israel Yonatan Beker 972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024